science wire



Results 1251 - 1300 of 1424.
« Previous 1 ... 22 23 24 25 26 27 28 ... 29 Next »

Health - Pharmacology - 24.10.2011
Relief of symptoms in up to 81% of patients with psoriasis
Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis In three Phase II trials, AIN457 provided a substantial increase in skin clearance in patients with moderate-to-severe plaque psoriasis[1-3] AIN457, a fully human anti-IL17A monoclonal antibody, offers a novel mechanism of action that suppresses the underlying inflammation in psoriasis[1-3] Approximately 2% of the world's

Pharmacology - Health - 17.10.2011
Novartis drug Gilenya
Novartis drug Gilenya (fingolimod) has more than 20,000 patient-years of exposure and shows up to 71% reduction in annualized relapse rates in MS patients with highly active disease Analyses presented at 5 th Joint Triennial Congress of ECTRIMS and ACTRIMS showed relapse rate reductions were consistent among subgroups of fingolimod-treated patients that had highly active disease in pivotal clinical trials Fingolimod demonstrated reductions in ra

Pharmacology - Health - 27.09.2011
New Novartis data show potential of respiratory portfolio to help COPD patients maintain active and productive lives
Studies show investigational once-daily NVA237 provides superior 24-hour bronchodilation and increases exercise endurance relative to placebo , Additional data show NVA237 significantly prolonged time to first moderate/ severe COPD exacerbation and reduced associated hospitalizations NVA237 submitted for EU approval under brand-name Seebri Breezhaler for treatment of chronic obstructive pulmonary disease (COPD) Basel , September 27, 2011 - Novar

Pharmacology - Health - 27.09.2011
Novartis receives approval in Japan for two innovative therapies, Gilenya in MS and Ilaris in CAPS
Gilenya first high efficacy oral therapy approved in Japan for the prevention of relapse and delay of progression of physical disability in adults with multiple sclerosis (MS) Ilaris the first drug a

Health - Pharmacology - 26.09.2011
Novartis drug Afinitor helps women with advanced breast cancer live significantly longer without their disease progressing
Everolimus combined with hormonal therapy more than doubled time without tumor growth and reduced risk of progression by 57% vs hormonal therapy alone Study shows everolimus significantly enhances benefit from hormonal therapy, representing important advance for women with postmenopausal ER+ breast cancer , Worldwide regulatory filings planned by the end of 2011 based on these data, marking the first submission for everolimus in breast cancer Ba

Health - Pharmacology - 25.09.2011
QTI571 significantly improved walking distance in patients with life-threatening pulmonary arterial hypertension
Phase III IMPRES study demonstrates potential benefits of QTI571 in patients who remain symptomatic despite treatment with two or more PAH therapies Evidence indicates that QTI571 targets an underlying cause of PAH by counteracting uncontrolled growth of arterial smooth muscle cells PAH is a debilitating disease of the heart and lungs affecting up to 260,000 people worldwide leading to heart failure and death , Basel, September 25, 2011 - Novart

Health - Pharmacology - 23.09.2011
Novartis drug Afinitor effective in patients with non-cancerous kidney tumors associated with TSC in Phase III trial
Study met primary endpoint of kidney tumor response rate with 42% of patients on everolimus experiencing a response versus 0% on placebo Kidney tumors are present in up to 80% of patients with tubero

Pharmacology - Health - 23.09.2011
Novartis gains positive CHMP opinion for Rasitrio
Rasitrio combines the only approved direct renin inhibitor, Rasilez, with the calcium channel blocker amlodipine, and the diuretic hydrochlorothiazide (HCT) In Phase III data, Rasitrio demonstrated s

Pharmacology - Life Sciences - 21.09.2011
New perspectives for TB treatment.
New perspectives for TB treatment.
Pyrazinamide—Old TB Drug Finds New Target More than 60 years after the discovery of pyrazinamide (PZA), a drug that is a mainstay of combination therapy for tuberculosis (TB), researchers have finally uncovered a mechanism of action that is convincing and novel. Stewart Cole (UPCOL - Chair of Microbial Pathogenesis ) comment (Science Perspective) on resent finding by Shi et al.

Health - Pharmacology - 16.09.2011
Study showed ACZ885 provided substantial symptom relief in 84% of patients with the most serious form of childhood arthritis
ACZ885, which neutralizes key inflammatory driver interleukin-1 beta , provided significant symptom improvement vs.

Business / Economics - Pharmacology - 13.09.2011
Novartis increases growth potential through integration of Alcon
Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division.

Health - Pharmacology - 08.09.2011
Novartis receives EU approval for Votubia , the first medication to treat children and adults with SEGA associated with TSC
Approval follows recent CHMP positive opinion based on Phase II study showing SEGA tumor reduction in patients with TSC Subependymal giant cell astrocytoma (SEGA) is a non-cancerous brain tumor that

Health - Pharmacology - 05.09.2011
Novartis drug Afinitor gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
Phase III trial showed Afinitor reduced risk of cancer progression by 65% vs.

Health - Pharmacology - 29.08.2011
Novartis International BioCamp spotlights how diversity spurs innovation across the company and inspires future science leaders
The interactive BioCamp program engages students around scientific advances and entrepreneurial opportunities The eighth annual event brings 60 top university students from 24 countries and territori

Pharmacology - Health - 29.08.2011
FDA requests additional clinical data on Novartis drug ACZ885 for the treatment of gouty arthritis
Agency issues Complete Response letter requesting more data to support approval; Novartis will continue to work with the FDA on next steps Novartis remains committed to studying ACZ885 in inflammator

Health - Pharmacology - 22.07.2011
Novartis drug Afinitor recommended by CHMP for EU approval to treat patients with advanced pancreatic neuroendocrine tumors
Phase III trial showed everolimus significantly delayed tumor growth in patients with advanced neuroendocrine tumors (NET) of pancreatic origin Everolimus represents a potentially new targeted approa

Health - Pharmacology - 15.07.2011
Novartis begins shipment of Fluvirin seasonal influenza vaccine to US customers for 2011-2012 influenza season
Novartis plans to ship over 30 million doses of Fluvirin vaccine to US customers for 2011-2012 season with sufficient supply to meet customer demand Early delivery allows for early vaccination of pri

Health - Pharmacology - 08.07.2011
Phase III trial of Novartis drug Afinitor met primary endpoint of reducing SEGA tumor size in patients with tuberous sclerosis
Largest Phase III study in tuberous sclerosis complex (TSC) showed 35% of patients treated with everolimus had a 50% or greater reduction in SEGA volume versus 0% on placebo Subependymal giant cell a

Health - Pharmacology - 05.07.2011
Novartis drug Afinitor met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need
Trial stopped early after positive interim results showed everolimus plus exemestane extended time without tumor growth Postmenopausal ER+HER2- metastatic breast cancer patients whose disease has pro

Pharmacology - Health - 01.07.2011
Novartis receives FDA approval for Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Arcapta is the only once-daily long-acting beta 2 -agonist (LABA) approved in US for maintenance treatment of airflow obstruction in patients with COPD Clinical studies with Arcapta showed sustained improvement in lung function; improvements were seen at 5-minutes after first dose Arcapta is approved with data demonstrating improvements in health-related quality of life COPD is a progressive and life-threatening lung disease that affects more th

Pharmacology - Health - 01.07.2011
Novartis receives approval in Japan for Onbrez Inhalation Capsules, a novel once-daily bronchodilator therapy for patients with COPD
Onbrez is the only once-daily long-acting beta 2 -agonist (LABA) approved in Japan for treatment of chronic obstructive pulmonary disease Clinical data show that Onbrez provides rapid and sustained i

Pharmacology - Health - 30.06.2011
Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD
GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p< 0.001) with comparable efficacy to open-label tiotropium at 12 weeks NVA237 shown to be well-tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) Phase III data support first regulatory submission for NVA237 by end of 2011 Basel, June 30, 2011 - Results from the pivotal Phase III GLOW2 clinical trial show that once-da

Health - Pharmacology - 24.06.2011
Novartis drug Votubia recommended by CHMP for approval in the EU for children and adults with SEGA associated with tuberous sclerosis
If approved, Votubia (everolimus) will be first medication in EU for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) CHMP opinion based on Phase II study o

Pharmacology - Health - 22.06.2011
FDA panel endorses efficacy but not safety of Novartis drug ACZ885 for gouty arthritis; did not support approval in proposed indication
Advisory committee strongly endorsed the efficacy of ACZ885 (canakinumab) Committee voted against approval of ACZ885 for proposed indication; potential identified for use in more narrow patient popul

Pharmacology - Business / Economics - 16.06.2011
Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia
Novartis AG holds groundbreaking ceremony with Minister of Economic Development of the Russian Federation, E. Nabiullina, Governor of Saint - Petersburg V. Matvienko, and Novartis AG CE

Pharmacology - Health - 16.06.2011
Novartis application for expanded Menveo indication from 2 months of age accepted for review by FDA
Submission includes data in more than 6,000 infants and toddlers worldwide Protecting infants is critical as they are at highest risk of contracting meningococcal disease Basel, June 16, 2011 - Novar

Health - Pharmacology - 09.06.2011
Novartis candidate vaccine Bexsero shows significant potential in providing broad coverage against meningococcal serogroup B infections
Pivotal study in more than 1,800 infants shows Bexsero induces robust immune response when given alone or with other routine vaccines in different vaccination schedules Meningococcal serogroup B disease has highest incidence in infants and young children and can lead to death within 24-48 hours of first symptoms Bexsero can help protect the majority of people at risk for infection, as data show the vaccine also induces robust immune response in

Health - Pharmacology - 06.06.2011
Novartis gains European Commission approval for Lucentis to treat vision loss due to macular edema secondary to RVO
Lucentis (ranibizumab) is first anti-VEGF approved for visual impairment due to macular edema secondary to branch- and central-retinal vein occlusion (RVO) Pivotal clinical data show rapid and signif

Health - Pharmacology - 05.06.2011
Novartis drug Glivec shows significant overall survival benefit for patients with GIST after three years of adjuvant treatment vs. one year
Data show 66% recurrence-free survival and 92% overall survival at five years following three years of adjuvant therapy with Glivec in patients with resected KIT+ GIST First large Phase III clinical trial to demonstrate survival benefits of extended treatment with Glivec for three years compared to one year following surgery Important finding for treatment of GIST patients who are at risk of recurrence following complete resection of primary tum

Pharmacology - Health - 04.06.2011
Novartis JAK inhibitor INC424 shows significant clinical benefit for myelofibrosis patients in two Phase III studies at ASCO
Myelofibrosis is a life-threatening blood cancer characterized by bone marrow failure, enlarged spleen and debilitating symptoms, including fatigue and pain Phase III trial (COMFORT-II) demonstrated INC424 significantly reduced enlarged spleen size, a major characteristic of the disease, when compared to best available therapy at 48 weeks A separate Phase III trial (COMFORT-I) of INC424 showed significant spleen size reduction and symptom improv

Pharmacology - Health - 01.06.2011
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Plenary presentation of Phase III study examining benefit of extended adjuvant treatment with Glivec for three years vs.

Health - Pharmacology - 25.05.2011
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate , Gouty arthritis, commonly referred to as gout, is an inflammatory disease affecting 1-4% of adults, causing severe pain and long-term consequences - Regulatory filings for the use of ACZ885 in gouty arthritis patients with limited treatment options have been submitted in the EU, US, Canada an

Pharmacology - 24.05.2011
Alcon wins Patanol US patent infringement lawsuit against Apotex
Patanol is the world's leading prescription eye drop used to treat the signs and symptoms of allergic conjunctivitis US court decision is an important milestone to defend Alcon's intellectual propert

Pharmacology - Business / Economics - 18.05.2011
Novartis provides restated consolidated income statement data for 2010 and Q1 2011 following the merger with Alcon; no change to total reported Group data
Basel, May 18, 2011 - Novartis provides unaudited restated and pro forma consolidated income statement data after the completion of the merger with Alcon, Inc. The segmental consolidated income statement data has been amended to reflect the new divisional structure following the Alcon merger. The new reporting structure will be effective from the second quarter of 2011.

Pharmacology - Health - 15.05.2011
Onbrez Breezhaler plus tiotropium is more effective than tiotropium alone in treatment of COPD
Phase III studies show once-daily Onbrez Breezhaler plus tiotropium improved lung function (measured by trough FEV 1 ) by up to 230 mL from baseline Results add to comprehensive data supporting Onbrez Breezhaler as an effective treatment for COPD with good safety profile Basel, May 15, 2011 - Results of two Phase III studies show that once-daily Onbrez Breezhaler (indacaterol) plus tiotropium produced a significantly greater improvement in lung

Pharmacology - Health - 11.05.2011
New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer
Basel, 11 May 2011 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer Vemurafenib is the first personalised investigational medicine to have shown

Health - Pharmacology - 11.05.2011
Novartis drug Votubia approved as first medication in Switzerland for SEGA, a benign brain tumor associated with tuberous sclerosis
Subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis (TS) primarily affect children and adolescents , Approval based on Phase II US study of 28 patients showing 75% of pati

Health - Pharmacology - 06.05.2011
Novartis gains FDA approval for Afinitor as first new treatment in nearly three decades for patients with advanced pancreatic NET
Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin Afinitor represents a new approach to treat a

Health - Pharmacology - 04.05.2011
New analysis representing largest available dataset highlights relative safety of Lucentis (ranibizumab) compared to unlicensed intravitreal Avastin (bevacizumab)
Basel, May 4, 2011 - A new Medicare analysis conducted by Johns Hopkins University presented today at the Association for Research in Vision and Ophthalmology (ARVO) meeting represents the largest av

Pharmacology - Health - 28.04.2011
Novartis receives EU approval for Rasilamlo , a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Rasilamlo combines in a single pill the only approved direct renin inhibitor, Rasilez, with the widely used calcium channel blocker amlodipin Data showed Rasilamlo provides greater blood pressure red

Pharmacology - Life Sciences - 19.04.2011
Using yeast to uncover a common drug's secrets
Using yeast to uncover a common drug’s secrets
An anti-inflammation drug's well-kept secrets have finally been uncovered thanks to a type of yeast; a discovery that will impact treatments for other diseases and limit side effects. Sulfasalazine is a frequently used drug, but its anti-inflammation mechanism has remained, to date, poorly understood.

Health - Pharmacology - 12.04.2011
Novartis drug Afinitor recommended by FDA oncology advisory committee for approval to treat advanced NET of pancreatic origin
Committee votes unanimously in favor of everolimus to treat patients with advanced neuroendocrine tumors (NET) of pancreatic origin Phase III results showed everolimus more than doubled median progre

Pharmacology - Health - 11.04.2011
Novartis discontinues clinical trial of Tasigna for investigational use in newly diagnosed patients with unresectable and/or metastatic GIST
Independent data monitoring committee recommends stopping ENESTg1 trial as interim efficacy results show Tasigna is unlikely to show superiority Novartis remains committed to advancing treatment options for patients with GIST Basel , April 11, 2011 - Novartis announced today it is discontinuing a Phase III trial of Tasigna (nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumors (GIST) based on the recommendation of an independent data monitoring committee.

Pharmacology - Health - 11.04.2011
Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
Gilenya delayed the progression of disability both for patients who were previously treated for their MS and for patients who had not received prior treatment 11 scientific abstracts on Gilenya effic

Pharmacology - Health - 08.04.2011
Novartis amends current US FDA application for Afinitor to seek indication for advanced neuroendocrine tumors of pancreatic origin
Basel, April 8 , 2011 - Novartis announced today that it has updated its supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for Afinitor (everolimus) tablets.

Pharmacology - Health - 31.03.2011
Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows
DEB025 plus standard of care (pegylated-interferon alfa 2a/ribavirin) showed superior viral cure vs standard of care alone (p=0.008) A cyclophilin inhibitor, DEB025 belongs to a new class of medicines that limit hepatitis C virus replication and have the potential to reshape hepatitis C therapy Phase III study with DEB025 commenced recently with previously untreated patients infected by the most common form of hepatitis C virus Basel, Mar

Pharmacology - Health - 23.03.2011
FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD
US Food and Drug Administration (FDA) extends review period for new drug application (NDA) by three months to July 2011 Additional time requested to complete review of the large amount of data from c

Business / Economics - Pharmacology - 22.03.2011
Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
Novartis acquires 85 percent stake in Tianyuan, one of the largest privately held vaccines companies in China Novartis to collaborate with Tianyuan on strengthening its existing product portfolio and

Pharmacology - Health - 21.03.2011
Novartis receives European Commission approval for Gilenya , the first oral multiple sclerosis treatment for use in the EU
Gilenya approved in the EU for people with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS Gilenya showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p<0.001) at one year Two-year, placebo-controlled study demonstrated that Gilenya significantly reduced the risk of disability pr

Health - Pharmacology - 18.03.2011
Novartis gains positive CHMP opinion for Lucentis (ranibizumab) to treat vision loss due to macular edema secondary to RVO
Lucentis recommended for approval in EU for visual impairment due to macular edema secondary to branch- and central-retinal vein occlusion (RVO) Pivotal data show rapid and significant improvements i
« Previous 1 ... 22 23 24 25 26 27 28 ... 29 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |